2m 2m 2m 2m 2m 2m 2m
Resmed (RMD)
NYSE
$191.31+$2.86 (+1.52%)
Price as of Jun 23, 2026 5:27 PM EDT- $27.3BMarket Cap
- -25.23%1-Year Change
- Medical Instruments & SuppliesIndustry
Resmed (RMD)
$191.31+$2.86 (+1.52%)
Annual
Quarterly
06/30/2025 | 06/30/2024 | 06/30/2023 | 06/30/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 4.5B -3.85% | 4.7B +10.95% | 4.2B +18.02% | 3.6B +11.93% | |
Cost of Revenue | 2.1B +3.02% | 2.0B +8.71% | 1.9B +20.18% | 1.6B +14.44% | |
Gross Profit | 3.1B +15.05% | 2.7B +12.72% | 2.4B +16.37% | 2.0B +10.07% | |
Sales and Marketing Expense | 991.0M +8.06% | 917.1M +4.94% | 874.0M +18.21% | 739.4M +10.29% | |
Research and Development Expense | -331.3M +7.73% | -307.5M +6.91% | -287.6M +13.43% | -253.6M +12.56% | |
Depreciation and Amortization Expense | 198.5M +12.21% | 176.9M +7.09% | 165.2M +3.48% | 159.6M +1.82% | |
Total Operating Expenses | 1.4B +2.56% | 1.3B +9.12% | 1.2B +19.51% | 1.0B +9.47% | |
Operating Profit | 1.7B +27.69% | 1.3B +16.61% | 1.1B +13.15% | 1.0B +10.69% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | -45.7M -3.53% | -47.4M +112.35% | -22.3M -6.99% | |
Interest Income and Expense and Net | 0 +100.00% | -45.7M -3.53% | -47.4M +112.35% | -22.3M -5.57% | |
Total Nonoperating Income and Expense | -7.8M -85.85% | -55.1M +82.39% | -30.2M -24.11% | -39.8M +98.86% | |
Income before Taxes | 1.7B +32.64% | 1.3B +14.81% | 1.1B +14.70% | 960.5M +8.69% | |
Income Taxes | 276.8M +13.53% | 243.8M +19.47% | 204.1M +12.74% | 181.0M -55.75% | |
Extraordinary Items | N/A N/A | N/A N/A | 2.3M 0.00% | 2.3M 0.00% | |
Net Income | 1.4B +37.20% | 1.0B +13.75% | 897.6M +15.15% | 779.4M +64.26% | |
Net Income from Continuing Operations Applicable to Common | 1.7B +32.64% | 1.3B +14.81% | 1.1B +14.70% | 960.5M +8.69% | |
Basic EPS and Net Income | 9.55 +37.61% | 6.94 +13.40% | 6.12 +14.61% | 5.34 +63.30% | |
Diluted EPS and Net Income | 9.51 +37.43% | 6.92 +13.63% | 6.09 +14.91% | 5.30 +63.58% | |
Basic Weighted Average Shares | 146.7M -0.21% | 147.0M +0.17% | 146.8M +0.48% | 146.1M +0.52% | |
Diluted Weighted Average Shares | 147.3M -0.14% | 147.6M +0.06% | 147.5M +0.28% | 147.0M +0.40% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 1.2B +407.40% | 238.4M +4.59% | 227.9M -16.74% | 273.7M -7.30% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 1.2B +407.40% | 238.4M +4.59% | 227.9M -16.74% | 273.7M -7.30% | |
Total Current Assets | 3.5B +48.69% | 2.4B -0.43% | 2.4B +22.59% | 1.9B +22.65% | |
Accumulated Depreciation | 705.3M -2.98% | 727.0M +8.83% | 668.0M +5.51% | 633.1M +1.76% | |
Property and Plant and Equipment and Net | 550.8M +0.50% | 548.0M +1.89% | 537.9M +7.96% | 498.2M +7.48% | |
Total Long-Term Assets | 4.7B +3.41% | 4.5B +2.98% | 4.4B +38.54% | 3.2B +0.35% | |
Total Assets | 8.2B +18.95% | 6.9B +1.79% | 6.8B +32.49% | 5.1B +7.78% | |
Income Taxes Payable | 132.3M +23.03% | 107.5M -1.73% | 109.4M +16.67% | 93.8M -74.72% | |
Total Short-Term Debt | 9.9M 0.00% | 9.9M -0.02% | 9.9M -0.14% | 9.9M -17.37% | |
Total Current Liabilities | 1.0B +11.91% | 910.7M +20.05% | 758.5M +10.04% | 689.3M -24.40% | |
Total Long-Term Debt | 658.4M -5.58% | 697.3M -51.28% | 1.4B +87.01% | 765.3M +18.96% | |
Total Long-Term Liabilities | 1.2B +8.17% | 1.1B -41.09% | 1.9B +78.17% | 1.0B +12.37% | |
Total Liabilities | 2.2B +9.87% | 2.0B -23.40% | 2.6B +51.10% | 1.7B -5.83% | |
Retained Earnings | 6.1B +21.83% | 5.0B +17.37% | 4.3B +17.69% | 3.6B +17.34% | |
Total Stockholders Equity | 6.0B +22.69% | 4.9B +17.78% | 4.1B +22.89% | 3.4B +16.46% | |
Total Shares Outstanding | 146.4M -0.35% | 146.9M -0.11% | 147.1M +0.45% | 146.4M +0.52% | |
Cash Flow | |||||
Cash from Operating Activities | 1.8B +25.00% | 1.4B +102.11% | 693.3M +97.44% | 351.1M -52.34% | |
Capital Expenditures | 89.9M -9.65% | 99.5M -16.89% | 119.7M -11.25% | 134.8M +31.27% | |
Cash from Investing Activities | -200.0M -25.85% | -269.8M -76.74% | -1.2B +404.46% | -229.9M +45.09% | |
Dividends Paid | 310.9M +10.12% | 282.3M +9.31% | 258.3M +5.27% | 245.3M +8.22% | |
Cash from Financing Activities | -606.3M -45.84% | -1.1B -364.69% | 422.9M +429.44% | -128.4M -83.21% | |
Financials Ratio | |||||
Gross Margin | 53.58% -5.47% | 56.67% +1.60% | 55.78% -1.40% | 56.57% -1.66% | |
Operating Margin | 37.41% +32.80% | 28.17% +5.11% | 26.80% -4.12% | 27.96% -1.11% | |
Return on Assets | 18.62% +24.23% | 14.99% -1.08% | 15.15% -4.51% | 15.87% +55.76% | |
Return on Equity | 25.86% +13.92% | 22.70% -5.26% | 23.96% -3.97% | 24.96% +41.55% | |
Revenue Growth | -3.85% -135.17% | 10.95% -39.26% | 18.02% +51.10% | 11.93% +47.07% | |
Current Ratio | 3.44 +32.86% | 2.59 -17.06% | 3.12 +11.40% | 2.80 +62.23% | |
Cash Ratio | 1.19 +353.50% | 0.26 -12.88% | 0.30 -24.35% | 0.40 +22.60% | |
Debt-to-Equity Ratio | 0.11 -22.97% | 0.15 -58.34% | 0.35 +51.28% | 0.23 +1.59% | |
Debt-to-Assets Ratio | 0.08 -20.51% | 0.10 -51.78% | 0.21 +40.30% | 0.15 +9.74% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow